Загрузка...
Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of advanced differentiated thyroid carcinoma (DTC). Resistance to sorafenib may appear under treatment and may be associated with increased aggressiveness of the neoplasia. The present study reports the case of a 65-year-old male...
Сохранить в:
| Опубликовано в: : | Oncol Lett |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
D.A. Spandidos
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5530175/ https://ncbi.nlm.nih.gov/pubmed/28781658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6395 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|